RIPK1

Last updated on: 23.09.2026

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

Definition This section has been translated automatically.

RIPK1 stands for "Receptor-interacting serine/threonine protein kinase 1." RIPK1 is a serine/threonine protein kinase and a key signaling protein involved in inflammatory responses and regulated cell death.

General information This section has been translated automatically.

RIPK1 has two functionally distinct roles: As a scaffold protein, RIPK1 supports, among other things, survival signals from the TNF receptor; when its kinase function is activated, it can contribute to the initiation of apoptosis or, via RIPK3 and MLKL, necroptosis. In the cytoplasmic ripoptosome , RIPK1 acts in conjunction with FADD and caspase-8.

Genetics and clinical significance: The RIPK1 gene, located on chromosome 6, encodes the protein of the same name, RIPK1. Biallelic loss-of-function variants can cause RIPK1 deficiency, leading to immunodeficiency and inflammatory diseases. Certain heterozygous variants, on the other hand, prevent the cleavage of RIPK1 by caspase-8 and lead to the autoinflammatory CRIA syndrome, which is characterized, among other things, by recurrent fever and lymphadenopathy.

Note(s) This section has been translated automatically.

As a key mediator of cell death and inflammatory processes, RIPK1 is a target for the development of highly selective small-molecule inhibitors. Potential applications of RIPK1 inhibitors are emerging for the treatment of monogenic and polygenic autoimmune, inflammatory, neurodegenerative, ischemic, and acute diseases, such as sepsis (Mifflin L et al. 2020).

Literature This section has been translated automatically.

  1. Chen Z et al. (2025) RIPK1 detects a shortage of S-adenosylmethionine to trigger cell death and inflammation. Cell Metab 37:1732-1749.e9.
  2. Dannappel M et al. (2014) RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513(7516):90–94.
  3. Mifflin L et al. (2020) Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov 19:553–571.

Last updated on: 23.09.2026